Protease/PAR-2 Signaling in Atopic Dermatitis Clin Invest 2006;116:1174-86. 77. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Bíró T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006;126:1705-18. 78. Costa R, Marotta DM, Manjavachi MN, Fernandes ES, Lima- Garcia JF, Paszcuk AF, et al. Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. Br J Pharmacol 2008;154:1094-103. 79. Steinhoff M, Stander S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003;139:1479-88. 80. Komatsu N, Tsai B, Sidiropoulos M, Saijoh K, Levesque MA, Takehara K, et al. Quantification of eight tissue kallikreins in the stratum corneum and sweat. J Invest Dermatol 2006;126:925-9. 81. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, et al. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 2004;24:4300-12. 82. Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW, et al. Genetic association between an AACC insertion in the 3’UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol 2004;123: 62-6. 83. Hansson L, Bäckman A, Ny A, Edlund M, Ekholm E, Ekstrand Hammarström B, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J Invest Dermatol 2002;118:444-9. 84. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001;29:175-8. 85. Mägert HJ, Ständker L, Kreutzmann P, Zucht HD, Reinecke M, Sommerhoff CP, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999;274:21499-502. 86. Hachem JP, Wagberg F, Schmuth M, Crumrine D, Lissens W, Jayakumar A, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 2006;126:1609-21. 87. Descargues P, Deraison C, Bonnart C, Kreft M, Kishibe M, Ishida-Yamamoto A, et al. Spink5-deficient mice mimic Nether- ton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 2005;37:56-65. 88. Bonnart C, Deraison C, Lacroix M, Uchida Y, Besson C, Robin A, et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest 2010;120:871-82. 89. Kato A, Fukai K, Oiso N, Hosomi N, Murakami T, Ishii M. Association of SPINK5 gene polymorphisms with atopic derma- titis in the Japanese population. Br J Dermatol 2003;148:665-9. 90. Vasilopoulos Y, Cork MJ, Teare D, Marinou I, Ward SJ, Duff GW, et al. A nonsynonymous substitution of cystatin A, a cys- teine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis. Allergy 2007;62:514-9. 91. Mauro T. SC pH: measurement, origins, and functions. In: Eilas P, Feingold K, editors. Skin Barrier. New York: Taylor & Francis Group; 2006. p.223-30. 92. Fluhr JW, Behne MJ, Brown BE, Moskowitz DG, Selden C, Mao-Qiang M, et al. Stratum corneum acidification in neonatal skin: secretory phospholipase A2 and the sodium/hydrogen anti- porter-1 acidify neonatal rat stratum corneum. J Invest Dermatol 2004;122:320-9. 93. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol 2006;19:296-302. 94. Rippke F, Schreiner V, Doering T, Maibach HI. Stratum cor- neum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus. Am J Clin Dermatol 2004;5:217-23. 95. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epi- dermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-6. 96. O’Regan GM, Sandilands A, McLean WH, Irvine AD. Filag- grin in atopic dermatitis. J Allergy Clin Immunol 2008;122:689- 93. 97. Fluhr JW, Elias PM, Man MQ, Hupe M, Selden C, Sundberg JP, et al. Is the filaggrin-histidine-urocanic acid pathway essen- tial for stratum corneum acidification? J Invest Dermatol 2010; 130:2141-4. 98. Roelandt T, Heughebaert C, Hachem JP. Proteolytically active allergens cause barrier breakdown. J Invest Dermatol 2008;128: 1878-80. 99. Kato T, Takai T, Fujimura T, Matsuoka H, Ogawa T, Muraya- ma K, et al. Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes. Allergy 2009;64:1366-74. 100. Hirasawa Y, Takai T, Nakamura T, Mitsuishi K, Gunawan H, Suto H, et al. Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol 2010;130:614-7. 101. Ohnemus U, Kohrmeyer K, Houdek P, Rohde H, Wladykowski E, Vidal S, et al. Regulation of epidermal tight-junctions (TJ) during infection with exfoliative toxin-negative Staphylococcus strains. J Invest Dermatol 2008;128:906-16. 102. Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thomp- son PJ, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 1999;104: 123-33. 103. Runswick S, Mitchell T, Davies P, Robinson C, Garrod DR. Pollen proteolytic enzymes degrade tight junctions. Respirology 2007;12:834-42. 104. Kawabata A, Kawao N. Physiology and pathophysiology of proteinase-activated receptors (PARs): PARs in the respiratory system: cellular signaling and physiological/pathological roles. J Pharmacol Sci 2005;97:20-4. 105. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, et al. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 2003;111:35-41. 106. Hyun E, Andrade-Gordon P, Steinhoff M, Vergnolle N. Pro- tease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut 2008;57:1222-9. 107. Kim H, Jeong S, Jeong M, Ahn J, Moon S, Lee S. The relation- ship of PAR2 and pruritus in end stage renal disease patients and the clinical effectiveness of soybean extracts containing moisturizer on epidermal permeability barrier in end stage renal disease patients. J Invest Dermatol 2010;130:S56. 108. Akiyama T, Carstens MI, Carstens E. Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itch. Pain 2010 Aug 13. (Epub ahead of print). 109. Kelso EB, Lockhart JC, Hembrough T, Dunning L, Plevin R, Hollenberg MD, et al. Therapeutic promise of proteinase-acti- vated receptor-2 antagonism in joint inflammation. J Pharmacol Yonsei Med J http://www.eymj.org Volume 51 Number 6 November 2010 821